Psilocybin with psychological support for treatment-resistant depression: six-month follow-up
Robin Carhart‐Harris(University of California, San Francisco), D.J. Nutt(Imperial College London), James Rucker(South London and Maudsley NHS Foundation Trust), David Erritzøe(Imperial College London), Stephen Pilling(Health Data Research UK), Michael Bloomfield(University College London Hospitals NHS Foundation Trust), H. Valerie Curran(MRC Cancer Unit), David Taylor(Barnes-Jewish Hospital), James A. Rickard(Barts Health NHS Trust), Amanda Feilding(Beckley Foundation), Mark Bolstridge(South London and Maudsley NHS Foundation Trust), Benjamin Forbes(King's College London), Camilla Day(Imperial College London), R. Watts(Imperial College London), Bruna Giribaldi(Imperial College London), Mendel Kaelen(Imperial College London)
Cited by 969
Related Papers
Treatment-Resistant Schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) Working Group Consensus Guidelines on Diagnosis and Terminology
|American Journal of Psychiatry|2016|1.1k
Neural correlates of the LSD experience revealed by multimodal neuroimaging
|Proceedings of the National Academy of Sciences|2016|880
Effects of Cannabis Use on Human Behavior, Including Cognition, Motivation, and Psychosis: A Review
|JAMA Psychiatry|2016|856
Ketamine use: a review
|Addiction|2011|638
Psilocybin for treatment-resistant depression: fMRI-measured brain mechanisms
|Scientific Reports|2017|586